Ionis Pharmaceuticals Geçmiş Kazanç Performansı

Geçmiş kriter kontrolleri 0/6

Ionis Pharmaceuticals şirketinin kazançları yıllık ortalama -38.3% oranında azalırken, Biotechs sektörünün kazançları yıllık 19.3% oranında artan oldu. Gelirler yıllık ortalama 5.4% oranında azalan oldu.

Anahtar bilgiler

-38.3%

Kazanç büyüme oranı

-37.9%

EPS büyüme oranı

Biotechs Sektör Büyümesi	17.0%
Gelir büyüme oranı	-5.4%
Özkaynak getirisi	-54.2%
Net Marj	-44.7%
Son Kazanç Güncellemesi	30 Sep 2024

Yakın geçmiş performans güncellemeleri

Recent updates

Ionis Pharmaceuticals: Catalysts Due In 2025/2026 Are Extremely Compelling

Oct 23

There Is A Reason Ionis Pharmaceuticals, Inc.'s (NASDAQ:IONS) Price Is Undemanding

Aug 24

Ionis Pharmaceuticals: Harnessing RNA-Targeted Therapies For Long-Term Shareholder Value

Aug 11

Health Check: How Prudently Does Ionis Pharmaceuticals (NASDAQ:IONS) Use Debt?

Jul 28

Ionis: Tough Run For Share Price Belies Multiple Reasons For Optimism

May 28

Analysts Have Made A Financial Statement On Ionis Pharmaceuticals, Inc.'s (NASDAQ:IONS) First-Quarter Report

May 09

Lacklustre Performance Is Driving Ionis Pharmaceuticals, Inc.'s (NASDAQ:IONS) Low P/S

Apr 14

Is Ionis Pharmaceuticals (NASDAQ:IONS) Using Debt Sensibly?

Mar 18

Ionis Pharmaceuticals 2023 Earnings Review: Short-Term Pain, Long-Term Gain

Feb 23

Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) Investors Are Less Pessimistic Than Expected

Dec 28

Gelir ve Gider Dağılımı

Ionis Pharmaceuticals nasıl para kazanır ve harcar. LTM bazında en son bildirilen kazançlara dayanmaktadır.

Kazanç ve Gelir Geçmişi

NasdaqGS:IONS Gelir, gider ve kazançlar (USD Millions )
Tarih	Gelir	Kazançlar	G+A Giderleri	Ar-Ge Giderleri
30 Sep 24	803	-359	230	3
30 Jun 24	813	-366	239	0
31 Mar 24	777	-385	220	0
31 Dec 23	788	-366	213	0
30 Sep 23	615	-409	210	586
30 Jun 23	631	-309	174	0
31 Mar 23	576	-329	162	0
31 Dec 22	587	-270	150	0
30 Sep 22	875	7	141	0
30 Jun 22	849	-28	137	0
31 Mar 22	841	-4	148	0
31 Dec 21	810	-29	186	0
30 Sep 21	661	-608	207	0
30 Jun 21	688	-550	245	0
31 Mar 21	708	-495	272	0
31 Dec 20	729	-444	354	0
30 Sep 20	933	94	299	0
30 Jun 20	940	145	290	0
31 Mar 20	959	169	293	0
31 Dec 19	1,123	281	287	0
30 Sep 19	821	433	269	0
30 Jun 19	799	402	278	0
31 Mar 19	752	366	269	0
31 Dec 18	600	277	245	0
30 Sep 18	575	-41	224	0
30 Jun 18	548	-38	182	0
31 Mar 18	543	9	138	0
31 Dec 17	514	19	108	0
30 Sep 17	507	42	81	0
30 Jun 17	499	52	64	0
31 Mar 17	426	-15	52	0
31 Dec 16	373	-60	49	0
30 Sep 16	238	-184	44	0
30 Jun 16	176	-227	42	0
31 Mar 16	258	-134	40	0
31 Dec 15	284	-88	37	0
30 Sep 15	317	14	31	0
30 Jun 15	312	23	27	0
31 Mar 15	249	-24	23	0
31 Dec 14	214	-39	20	0
30 Sep 14	172	-94	18	0
30 Jun 14	151	-92	17	0
31 Mar 14	132	-90	16	0
31 Dec 13	147	-61	15	0

Kaliteli Kazançlar: IONS şu anda kârlı değil.

Büyüyen Kar Marjı: IONS şu anda kârlı değil.

Serbest Nakit Akışı ve Kazanç Analizi

Geçmiş Kazanç Büyüme Analizi

Kazanç Eğilimi: IONS kârlı değildir ve zararlar son 5 yılda yılda 38.3% oranında artmıştır.

Büyüme Hızlandırma: IONS 'un son bir yıldaki kazanç büyümesinin 5 yıllık ortalamasıyla karşılaştırılması mümkün değil çünkü şu anda kârlı değil

Kazançlar vs. Sektör: IONS kârlı olmadığından, geçmiş yıl kazanç büyümesinin Biotechs sektörüyle ( 16.6% ) karşılaştırılması zorlaşıyor.

Özkaynak Getirisi

Yüksek ROE: IONS hissesi şu anda kârlı olmadığından negatif Özsermaye Getirisi'ne ( -54.16% ) sahiptir.

Ionis Pharmaceuticals Geçmiş Kazanç Performansı

Geçmiş kriter kontrolleri 0/6

Anahtar bilgiler

Yakın geçmiş performans güncellemeleri

Third quarter 2024 earnings: EPS and revenues exceed analyst expectations

Second quarter 2024 earnings: EPS and revenues exceed analyst expectations

First quarter 2024 earnings: EPS exceeds analyst expectations while revenues lag behind

Full year 2023 earnings: EPS and revenues exceed analyst expectations

Third quarter 2023 earnings: EPS in line with analyst expectations despite revenue beat

Second quarter 2023 earnings: EPS and revenues exceed analyst expectations

Recent updates

Independent Chairman of the Board notifies of intention to sell stock

Third quarter 2024 earnings: EPS and revenues exceed analyst expectations

Ionis Announces Pivotal Phase 3 Trial Design for ION582 in Angelman Syndrome

Ionis Pharmaceuticals: Catalysts Due In 2025/2026 Are Extremely Compelling

Astrazeneca and Ionis' Wainzua (Eplontersen) Recommends Approval by the Committee for Medicinal Products for Human Use in the European Union

Ionis Pharmaceuticals, Inc. Announces Zilganersen Granted U.S. FDA Fast Track Designation for People Living with Alexander Disease

Ionis Pharmaceuticals, Inc. has filed a Follow-on Equity Offering in the amount of $500 million.

Ionis Pharmaceuticals, Inc. has completed a Follow-on Equity Offering in the amount of $500.25 million.

There Is A Reason Ionis Pharmaceuticals, Inc.'s (NASDAQ:IONS) Price Is Undemanding

Ionis Pharmaceuticals: Harnessing RNA-Targeted Therapies For Long-Term Shareholder Value

New minor risk - Shareholder dilution

Second quarter 2024 earnings: EPS and revenues exceed analyst expectations

Ionis Pharmaceuticals, Inc. Reaffirms Earnings Guidance for the Year 2024

Health Check: How Prudently Does Ionis Pharmaceuticals (NASDAQ:IONS) Use Debt?

Ionis Pharmaceuticals, Inc. Announces Positive Detailed Results from the HALOS Study of ION582 in People with Angelman Syndrome

Insufficient new directors

Ionis Pharmaceuticals, Inc. Announces olezarsen FCS New Drug Application Accepted for Priority Review and Enrollment in Phase 3 sHTG Program Completed

Independent Director notifies of intention to sell stock

Ionis Pharmaceuticals, Inc. Presents Positive Results from OASIS-HAE and OASISplus Studies of Investigational Medicine Donidalorsen in Patients with Hereditary Angioedema

Ionis: Tough Run For Share Price Belies Multiple Reasons For Optimism

Biogen and Ionis Announce Topline Phase 1/2 Study Results of Investigational Drug in Amyotrophic Lateral Sclerosis

Lead Independent Director exercised options to buy US$612k worth of stock.

Analysts Have Made A Financial Statement On Ionis Pharmaceuticals, Inc.'s (NASDAQ:IONS) First-Quarter Report

Ionis Pharmaceuticals, Inc. Reaffirms Financial Guidance for the Year 2024

First quarter 2024 earnings: EPS exceeds analyst expectations while revenues lag behind

Ionis Pharmaceuticals, Inc., Annual General Meeting, Jun 06, 2024

Lacklustre Performance Is Driving Ionis Pharmaceuticals, Inc.'s (NASDAQ:IONS) Low P/S

Ionis Presents Positive Results from Phase 3 Balance Study of Olezarsen for Familial Chylomicronemia Syndrome

Is Ionis Pharmaceuticals (NASDAQ:IONS) Using Debt Sensibly?

Ionis Pharmaceuticals, Inc. Announces Positive Results from Phase 2 Study of ION224

Ionis Pharmaceuticals, Inc. Announces Executive Changes

Ionis Pharmaceuticals 2023 Earnings Review: Short-Term Pain, Long-Term Gain

Full year 2023 earnings: EPS and revenues exceed analyst expectations

Ionis Pharmaceuticals, Inc. Provides Earnings Guidance for the Year 2024

Ionis Pharmaceuticals, Inc. Announces U.S. Food and Drug Administration Grants Orphan Drug Designation to the Investigational Medicine Olezarsen for the Treatment of FCS

Founder recently sold US$1.2m worth of stock

Ionis Pharmaceuticals, Inc. Announces Positive Topline Results from Phase 3 Oasis-Hae Study of Investigational Donidalorsen in Patients with Hereditary Angioedema

Founder notifies of intention to sell stock

Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) Investors Are Less Pessimistic Than Expected

Founder notifies of intention to sell stock

Ionis Pharmaceuticals, Inc. Announces U.S. Food and Drug Administration Approves Ionis and AstraZeneca's WAINUA

Insider notifies of intention to sell stock

Ionis Pharmaceuticals, Inc. Appoints Michael Yang as a Member of Board

Ionis Pharmaceuticals (NASDAQ:IONS) Has Debt But No Earnings; Should You Worry?

A Look At The Intrinsic Value Of Ionis Pharmaceuticals, Inc. (NASDAQ:IONS)

Ionis Pharmaceuticals, Inc. Shares Positive Clinical Update from Ongoing Trial of Ion582 for Angelman Syndrome

Ionis Presents Positive Two-Year Results from the Phase 2 Open-Label Extension Study of Donidalorsen in Patients with Hereditary Angioedema

Ionis Pharmaceuticals, Inc. Provides Earnings Guidance for the Year 2023

Third quarter 2023 earnings: EPS in line with analyst expectations despite revenue beat

Senior Strategic Advisor & Director notifies of intention to sell stock

Ionis Pharmaceuticals, Inc. Announces Positive Olezarsen Topline Results from Phase 3 Study in People with Facilitate Chylomicronemia Syndrome

Second quarter 2023 earnings: EPS and revenues exceed analyst expectations

Ionis Pharmaceuticals (NASDAQ:IONS) Has Debt But No Earnings; Should You Worry?

Ionis Completes Enrollment in Phase 3 Cardio-TTRansform Study in Patients with TTR-Mediated Amyloid Cardiomyopathy

Ionis Pharmaceuticals, Inc. to Report Q2, 2023 Results on Aug 09, 2023

Ionis Pharmaceuticals, Inc. Announces Positive Topline, 85-Week Data from the Phase 3 Neuro-Ttransform Study in Patients with Hereditary Transthyretin-Mediated Amyloid Polyneuropathy

Founder notifies of intention to sell stock

Ionis Pharmaceuticals, Inc. Announces New Data Highlight Potential Benefit of SPINRAZA® (nusinersen) in Infants and Toddlers with Unmet Medical Needs After Gene Therapy

Ionis Pharmaceuticals, Inc. Announces Positive Donidalorsen Late-Stage Clinical Progress in HAE

Founder notifies of intention to sell stock

Is Ionis Pharmaceuticals (NASDAQ:IONS) Using Debt Sensibly?

First quarter 2023 earnings: EPS and revenues exceed analyst expectations

Price target decreased by 7.2% to US$47.48

Full year 2022 earnings: EPS exceeds analyst expectations

Founder recently sold US$1.0m worth of stock

Ionis Pharmaceuticals, Inc. Announces GSK Has Advanced Bepirovirsen into Phase 3 Development

Ionis Receives FDA Fast Track Designation for Olezarsen in Patients with Familial Chylomicronemia Syndrome

Founder exercised options and sold US$990k worth of stock

Does Ionis Pharmaceuticals (NASDAQ:IONS) Have A Healthy Balance Sheet?